SEC Filings TLDR Banner

Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.

Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.

Filter by Form Type:
All346-K8-K10-Q144Schedule 13GSchedule 13G/ASchedule 13DSchedule 13D/A
Industry:Biotechnologyβœ•
Previous Page1819202122232425Next Page
2026-03-24RVPHWSCHEDULE 13D/AAmendment No. 13 to Schedule 13D for REVIVA PHARMACEUTICALS HOLDINGS, INC.MEDIUM
This filing is an amendment to a previous Schedule 13D, filed by Parag Saxena, regarding his beneficial ownership of Reviva Pharmaceuticals Holdings, Inc. common stock. As of March 24, 2026, Mr. Saxena beneficially owns 363,280 shares, representing approximately 2.8% of the outstanding shares. This ownership includes d...
Biotechnologyownership +2.80%
2026-03-24REVIVA PHARMACEUTICALS HOLDINGS, INC.SCHEDULE 13D/AAmendment No. 13 to Schedule 13D for REVIVA PHARMACEUTICALS HOLDINGS, INC.DuplicateMEDIUM
This filing is an amendment to a previous Schedule 13D, filed by Parag Saxena, regarding his beneficial ownership of Reviva Pharmaceuticals Holdings, Inc. common stock. As of March 24, 2026, Mr. Saxena beneficially owns 363,280 shares, representing approximately 2.8% of the outstanding shares. This ownership includes d...
Biotechnologyownership +2.80%
2026-03-23ACRVSCHEDULE 13D/AACRV Schedule 13D/A Filing SummaryMEDIUM
This filing is an amendment to a previous Schedule 13D, reporting a dilution in beneficial ownership of ACRIVON THERAPEUTICS, INC. common stock by RA Capital Management, L.P. and related entities. The reporting persons, including RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund...
Micro CapBiotechnologyownership +21.60%
2026-03-23CASISCHEDULE 13D/AAmendment to Schedule 13D Filing for CASI Pharmaceuticals, Inc.HIGH
This filing is an amendment to a Schedule 13D, relating to the ordinary shares of CASI Pharmaceuticals, Inc. The amendment details a convertible promissory note purchase agreement dated December 11, 2025, where ETP Global III Fund L.P. purchased a convertible note with a principal amount of US$5 million on February 19,...
Nano CapBiotechnologyownership +7.60%
Previous Page1819202122232425Next Page